Ligands of peroxisome proliferator-activated receptor γ induce apoptosis in multiple myeloma

被引：39

作者：

Eucker, J ^{[1
]}

Bängeroth, K ^{[1
]}

Zavrski, I ^{[1
]}

Krebbel, H ^{[1
]}

Zang, CB ^{[1
]}

Heider, U ^{[1
]}

Jakob, C ^{[1
]}

Elstner, E ^{[1
]}

Possinger, K ^{[1
]}

Sezer, O ^{[1
]}

机构：

[1] Univ Hosp Charite, Dept Hematol & Oncol, D-10117 Berlin, Germany

来源：

ANTI-CANCER DRUGS | 2004年 / 15卷 / 10期

关键词：

apoptosis; chemotherapy; multiple myeloma; peroxisome proliferator-activated receptor; PPAR-gamma;

D O I：

10.1097/00001813-200411000-00004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The activation of proliferator-activated receptor gamma (PPAR-y) by its natural and synthetic ligands induces apoptosis in several tumor cell lines, including malignant B-lineage cells. We investigated whether treatment with pioglitazone (PGZ), rosiglitazone (RGZ) or 15-deoxy-Delta(12,14-) prostaglandin J(2) (15d-PGJ(2)) inhibited tumor cell growth in five human multiple myeloma cell lines (LP-1, U-266, RPMI-8226-S, OPM-2 and IM-9) and human bone marrow myeloma cells expressing PPAR-gamma protein. MTT assays revealed growth arrest induced by the natural activator of PPAR-gamma 15d-PGJ(2) and a lower anti proliferative effect with thiazolidinediones (PGZ and RGZ) in a dose-dependent manner. Induction of apoptosis was indicated by Annexin-V staining. At a dose of 50 muM, 15d-PGJ(2) led to a high rate of apoptosis in all cell lines (60-92%). Furthermore, induction of apoptosis in sorted bone marrow plasma cells from myeloma patients was detected. Thiazolidinediones comprise anti-myeloma activity in vitro and should be explored further for the treatment of multiple myeloma. (C) 2004 Lippincott Williams Wilkins.

引用

页码：955 / 960

页数：6

共 31 条

[1] Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation [J].

Adams, M ;

Montague, CT ;

Prins, JB ;

Holder, JC ;

Smith, SA ;

Sanders, L ;

Digby, JE ;

Sewter, CP ;

Lazar, MA ;

Chatterjee, VKK ;

O'Rahilly, S .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3149-3153

[2]

Asou H, 1999, INT J ONCOL, V15, P1027

[3] Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis [J].

Bharti, AC ;

Shishodia, S ;

Reuben, JM ;

Weber, D ;

Alexanian, R ;

Raj-Vadhan, S ;

Estrov, Z ;

Talpaz, M ;

Aggarwal, BB .

BLOOD, 2004, 103 (08) :3175-3184

[4]

Chang TH, 2000, CANCER RES, V60, P1129

[5] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].

Child, JA ;

Morgan, GJ ;

Davies, FE ;

Owen, RG ;

Bell, SE ;

Hawkins, K ;

Brown, J ;

Drayson, MT ;

Selby, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883

[6] Peroxisome proliferator-activated receptors: Nuclear control of metabolism [J].

Desvergne, B ;

Wahli, W .

ENDOCRINE REVIEWS, 1999, 20 (05) :649-688

[7] Thalidomide analogs as emerging anti-cancer drugs [J].

Dredge, K ;

Dalgleish, AG ;

Marriott, JB .

ANTI-CANCER DRUGS, 2003, 14 (05) :331-335

[8] Novel therapeutic approach:: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells [J].

Elstner, E ;

Williamson, EA ;

Zang, C ;

Fritz, J ;

Heber, D ;

Fenner, M ;

Possinger, K ;

Koeffler, HP .

BREAST CANCER RESEARCH AND TREATMENT, 2002, 74 (02) :155-165

[9] Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice [J].

Elstner, E ;

Müller, C ;

Koshizuka, K ;

Williamson, EA ;

Park, D ;

Asou, H ;

Shintaku, P ;

Said, JW ;

Heber, D ;

Koeffler, HP .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8806-8811

[10]

Eucker Jan, 2003, Anticancer Drugs, V14, P793

← 1 2 3 4 →